Trial
NCT04958031
A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AbbVie
Collaborators
—
Condition
Apathy in Dementia
Intervention
CVL-871 1.0 mg
Why stopped
Sponsor Decision - Not Safety Related
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-11